WallStreetZenWallStreetZen

NASDAQ: AVGR
Avinger Inc Stock

$1.76+0.06 (+3.53%)
Updated Jul 18, 2024
AVGR Price
$1.76
Fair Value Price
N/A
Market Cap
$3.00M
52 Week Low
$1.59
52 Week High
$18.00
P/E
-0.11x
P/B
-0.74x
P/S
0.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.62M
Earnings
-$19.19M
Gross Margin
22.4%
Operating Margin
-228.91%
Profit Margin
-211.6%
Debt to Equity
-5.16
Operating Cash Flow
-$15M
Beta
0.76
Next Earnings
Jul 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AVGR Overview

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AVGR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AVGR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
AVGR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
AVGR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AVGR due diligence checks available for Premium users.

Be the first to know about important AVGR news, forecast changes, insider trades & much more!

AVGR News

Valuation

AVGR fair value

Fair Value of AVGR stock based on Discounted Cash Flow (DCF)
Price
$1.76
Fair Value
$4.48
Undervalued by
60.71%
AVGR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AVGR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.11x
Industry
54.44x
Market
29.86x

AVGR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.74x
Industry
3.62x

AVGR's financial health

Profit margin

Revenue
$1.9M
Net Income
-$5.5M
Profit Margin
-197.6%
AVGR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AVGR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$16.9M
Liabilities
$20.9M
Debt to equity
-5.16
AVGR's short-term liabilities ($20.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVGR's short-term assets ($14.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVGR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVGR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.7M
Investing
$0.0
Financing
$6.6M
AVGR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AVGR vs Medical Stocks

TickerMarket Cap1d %P/EP/B
AVGR$3.00M+3.53%-0.11x-0.74x
STSS$3.37M-3.15%-0.35x0.49x
POAI$4.80M0.00%-0.32x1.18x
LUCY$5.43M-16.53%-0.51x1.39x
GCTK$8.55M-1.89%-0.76x22.73x

Avinger Stock FAQ

What is Avinger's quote symbol?

(NASDAQ: AVGR) Avinger trades on the NASDAQ under the ticker symbol AVGR. Avinger stock quotes can also be displayed as NASDAQ: AVGR.

If you're new to stock investing, here's how to buy Avinger stock.

What is the 52 week high and low for Avinger (NASDAQ: AVGR)?

(NASDAQ: AVGR) Avinger's 52-week high was $18.00, and its 52-week low was $1.59. It is currently -90.22% from its 52-week high and 11.04% from its 52-week low.

How much is Avinger stock worth today?

(NASDAQ: AVGR) Avinger currently has 1,702,226 outstanding shares. With Avinger stock trading at $1.76 per share, the total value of Avinger stock (market capitalization) is $3.00M.

Avinger stock was originally listed at a price of $1,620,000.00 in Jan 30, 2015. If you had invested in Avinger stock at $1,620,000.00, your return over the last 9 years would have been -100%, for an annualized return of -78.26% (not including any dividends or dividend reinvestments).

How much is Avinger's stock price per share?

(NASDAQ: AVGR) Avinger stock price per share is $1.76 today (as of Jul 18, 2024).

What is Avinger's Market Cap?

(NASDAQ: AVGR) Avinger's market cap is $3.00M, as of Jul 19, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Avinger's market cap is calculated by multiplying AVGR's current stock price of $1.76 by AVGR's total outstanding shares of 1,702,226.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.